← Back to patent-cliff list
Azenosertib
Tier C — Watch / tradeAzenosertib
Zentalis Pharmaceuticals LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：WEE1
Indications (approved)：Ovarian cancer, 浆液性囊腺癌, 子宫肿瘤, Pancreatic cancer, 胰腺导管癌, Solid tumour, Oesophageal cancer, Gastric cancer
Regional status
US
Phase III
2026-04-17
EU
Phase III
2026-04-17
China
Phase I
2021-08-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Azenosertib?
Approved indications include: Ovarian cancer, 浆液性囊腺癌, 子宫肿瘤, Pancreatic cancer, 胰腺导管癌, Solid tumour, Oesophageal cancer, Gastric cancer.
When does the Azenosertib patent expire?
No public expiry year is available for Azenosertib yet; this page updates once verified.
How do I get a quote for Azenosertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29